PHARMACY

Analysis shows pain reduction for fibromyalgia patients using Lyrica

BY Diana Alickaj

CHICAGO A pooled analysis presented at the annual Academy of Neurology meeting reports that Pfizer’s Lyrica reduced pain in patients with fibromyalgia, whether or not they experienced symptoms of anxiety or depression.

The results were determined by analysis of data from three clinical trials that used a placebo as a control ranging from eight weeks, to 13 weeks and finally 14 weeks in more than 2,000 patients that had fibromyalgia. According to published reports, they also studied different dosages given to patients and where asked to measure their pain from a scale of zero to 10. The analysis confirmed that pain reduction was the greatest change in patients who used the drug regardless of whether they still had feelings of depression or anxiety.

According to published reports, Fibromyalgia is the most common, chronic pain condition in the United States, and patients who have it usually experience symptoms of poor sleep, stiffness and fatigue.

According to Dr. Lesly Arnold, one the authors of the study and associate professor in the department of psychiatry at the University of Cincinnati Medical Center, “The data showed that Lyrica reduced fibromyalgia pain, and alleviating that pain was associated with patients’ overall feeling of well-being. Understandably, many patients with a chronic pain condition, such as fibromyalgia, also experience depression and anxiety, and importantly we found that Lyrica helped reduce pain in patients regardless of the presence of symptoms of these co-morbid conditions.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Combination of Celebrex and Lipitor may prove effective in fighting prostate cancer

BY Diana Alickaj

WASHINGTON A new combination between the drugs Celebrex, which lowers cholesterol, and Lipitor, an anti-inflammatory drug, can be used in controlling prostate cancer before it becomes deadly, according to published reports.

The study first cultured prostate tumors in mice, and then gave the mice either Lipitor or Celebrex, or a combination of the two. All proved to be successful in halting cancer growth. The study also found that putting a combination of Lipitor and Celebrex in lower doses was most effective. Scientists have yet to find why these two combinations have such a positive effect on fighting prostate cancer.

Prostate cancer is the second-leading cancer killer in men, and the presence of the two drugs may help stop the progression of the cancer before it gets worse, according to the study.

Even though this discovery has gone only through preliminary trials, many are excited by the positive implications it may have for prostate cancer. According to K. Scott Coffield, a professor of surgery at Texas A&M Health Science Center College of Medicine and a urologist-oncologist at Scott & White, “They need to come up with the molecular mechanics and then take it back to clinical trials. It’s early but it’s interesting and that’s wonderful.”

The research will be presented at the American Association for Cancer Research’s annual meeting in San Diego.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Snabes tapped as BioSante Pharmaceuticals vice president of clinical development

BY Diana Alickaj

LINCOLNSHIRE, Ill. BioSante Pharmaceuticals announced Michael Snabes as the company’s new vice president of clinical development, according to published reports.

Snabes will be responsible for the development of LibiGel, which is a testosterone gel for the treatment of female sexual dysfunction. Snabes has a history with BioSante as he served as medical consultant of BioSante since November 2005, where he focused on clinical and regulatory matters, according to published reports.

He is a board certified reproductive endocrinologist, and has a Ph.D. in physiology and reproductive endocrinology. According to published reports, he also played major role in the submission of BioSante’s New Drug Application Elestrin, which now has been approved fully by the Food and Drug Administration.

“We are very pleased that Michael has agreed to accept this position with BioSante,” said Stephen Simes, president and chief executive officer of BioSante. “Michael has been an important part of our clinical team for more than two years and his full-time involvement will help us to implement fully and accelerate our development of LibiGel in the treatment of FSD, specifically hypoactive sexual desire disorder in menopausal women.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?